A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: ARcare Center for Clinical Research - Conway, Conway, Arkansas +3 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Recruiting
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2023
Locations: ARcare Center for Clinical Research, Conway, Arkansas +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
Recruiting
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/01/2023
Locations: Arcare Center for Clinical Research, Conway, Arkansas +1 locations
Conditions: NASH
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2023
Locations: Arkansas Gastroenterology, North Little Rock, Arkansas
Conditions: NASH, Cirrhosis, Liver